RxDoctor Payments Data

John Millett, MD

Family Medicine · Walker, MINPI 1386696664

Payments from drug & device makers

$12,808in general payments, 2019–2025

Across 800 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$12,73099%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,808 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$38,316
Medicare patients
66
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$63,448
JardianceEmpagliflozin24$37,706
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$34,623
MounjaroTirzepatide31$32,771
TrulicityDulaglutide18$30,396
FarxigaDapagliflozin Propanediol25$24,402
XareltoRivaroxaban18$24,221
JanuviaSitagliptin Phosphate18$21,827
OzempicSemaglutide12$14,294
Spiriva RespimatTiotropium Bromide13$6,514
Atorvastatin Calcium268$4,714
Rosuvastatin Calcium144$3,324
Metoprolol Succinate131$3,290
Qvar RedihalerBeclomethasone Dipropionate12$3,268
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,186$63,44860 claims
Lilly USA, LLCMounjaro, Trulicity$1,031$63,16749 claims
Boehringer IngelheimJardiance, Spiriva Respimat$1,048$44,22037 claims
GSKTrelegy Ellipta$796$34,62327 claims
AstraZenecaFarxiga$1,338$24,40225 claims
Johnson & JohnsonXarelto$122$24,22118 claims
MerckJanuvia$388$21,82718 claims
Novo NordiskOzempic$1,161$14,29412 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$365$3,26812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Walker

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →